Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: J Thorac Oncol. 2015 Sep;10(9):1301–1310. doi: 10.1097/JTO.0000000000000617

Figure 3.

Figure 3

Overall survival (OS) of combination of CD10+ neutrophil and CD20+ lymphocyte infiltration in the validation cohort

(A) OS of patients with high CD10+ neutrophil and low CD20+ lymphocyte infiltration (5-year OS, 46%) was relatively worse compared with those with low CD10/low CD20 (5-year OS, 58%; P = 0.069; HR = 0.61; 95% CI = 0.36–1.04), low CD10/high CD20 (5-year OS, 84%; P = 0.10; HR = 0.55; 95% CI = 0.27–1.13), and high CD10/high CD20 (5-year OS, 71%; P = 0.092; HR = 0.52; 95% CI = 0.24–1.11). (B) OS of patients with high CD10/CD20 risk index was significantly worse (n = 30; 5-year OS, 46%) than those with low risk index (n = 112; 5-year OS, 66%; P = 0.032; HR = 0.58; 95% CI = 0.35–0.96).